US Open: Nasdaq rebounds after the largest decline since 19-month 🔼 Lam Research surges 12%

Moderna (MRNA) reported Q3 2026 EPS of $0.38, beating estimates by $1.48. Revenue rose 29.2% YoY to $1.31B, driven by international COVID-19 vaccine sales. The company raised its 2026 sales outlook to 15-25% growth and reduced R&D spending plans. Shares rose in pre-market trading. Key products include mFlusiva and mCoflu vaccines, with mixed pipeline results.

Lam Research announced a $25 billion stock buyback program, but the authorization is flexible and non-binding. The company's board approved repurchases up to $25 billion, with no expiration date or obligation to spend the full amount. Buybacks can boost earnings per share without increasing profits, but actual repurchases may not match the authorized amount. The announcement follows a semiconductor selloff, reflecting management's capital-return flexibility.

WHO adds two Ebola vaccines, ChAdOx1 and mRNA-1469, to clinical trial in DRC. Developed by Oxford/Serum Institute and Moderna, they target the Bundibugyo virus. WHO's advisory group recommended further evaluation. Trial led by Institut National de Recherche Biomédicale and others. Current outbreak has caused over 4,600 cases and 2,100 deaths.

Moderna (MRNA) reported a $162M Q3 profit, reversing a $200M loss from a year earlier. Revenue rose 29% to $1.3B, while R&D costs fell 27% to $583M. GAAP EPS was $0.38, up from a loss of $0.51. The company raised its 2026 revenue growth outlook to 15-25%. Stock rose 8% on the news.

Moderna reported a 29% revenue increase to $1.3 billion for the quarter, driven by global COVID-19 vaccine sales. CFO Jamey Mock attributed growth to higher uptake of mNEXSPIKE and Spikevax. U.S. revenue is declining, but global expansion is leading sales. Moderna raised annual revenue expectations to 15-25%. Analysts noted strong vaccine sales and potential market share gains in the EU post-Pfizer's contract expiration.

Moderna (MRNA) shares rose 8% after Q3 revenue increased 29% to $1.31B, driven by international Covid vaccine sales. The company raised its 2026 revenue outlook to 15%-25%. Pfizer (PFE) and BioNTech (BNTX) reported weaker Q3 sales for their rival vaccine.